Pretreatment platelet count is a prognostic marker in lung cancer
Based on data from 7,908 lung cancer patients, a recent study shows that both low and high platelet counts are adverse prognostic factors in NSCLC. In low count showed an 75% increased risk of death and 24% in high count. In SCLC, low count is an even stronger marker with a 271% increased risk of death.
Brænder du for at skrive?
Vil du gerne dele din forskning eller dine kliniske erfaringer med dine kollegaer inden for netop dit speciale? Har du en ide til en artikel, som du gerne vil udgive hos os? Send redaktionen en mail på redaktion@bpno.dk
Send mail til redaktionen